Hemogenyx Pharmaceuticals (LSE:HEMO) has confirmed plans to re-appoint PKF Littlejohn LLP as its external auditor for the financial year ending December 2025. The decision follows a formal tender process and has been recommended by the company’s Audit Committee. Final approval remains subject to a shareholder vote.
The re-appointment is in line with mandatory lead audit partner rotation rules and reflects Hemogenyx’s compliance with public interest entity requirements, reinforcing its commitment to strong governance and transparent financial oversight.
About Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a London-based, publicly traded clinical-stage biopharmaceutical company with subsidiaries in New York. The business is dedicated to developing innovative therapies for blood and autoimmune diseases, leveraging multiple product candidates and proprietary platform technologies to advance novel treatments.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Leave a Reply